404
Chapter 11
95. Webber BL, Heise H, Neifeld JP, et al. Risk of subsequent contralateral
breast carcinoma in a population of patients with
in situ
breast carci-
noma.
Cancer
1981;47:2928–2932.
96. Gump FE, Jicha DL, Ozello L. Ductal carcinoma
in situ
(DCIS): a re-
vised concept.
Surgery
1987;102:790–795.
97. Andersen JA, Nielsen M, Blichert-Toft M. The growth pattern of
in
situ
carcinoma in the female breast.
Acta Oncol
1988;27:739–743.
98. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology
of the human breast with special reference to possible precancerous
lesions.
J Natl Cancer Inst
1975;55:231–273.
99. Barsky SH, Siegal GP, Jannotta F, et al. Loss of basement membrane
components by invasive tumors but not by their benign counterparts.
Lab Invest
1983;49:140–147.
100. Henning K, Berndt A, Katenkamp D, et al. Loss of laminin-5 in
the epithelium-stroma interface: an immunohistochemical marker
of malignancy in epithelial lesions of the breast.
Histopathology
1999;34:305–309.
101. Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal
carcinoma.
Arch Pathol Lab Med
1996;100:81–85.
102. Sternlicht MD, Kedeshian P, Shao ZM, et al. The human myoepithelial
cell is a natural tumor suppressor.
Clin Cancer Res
1997;3:1949–1958.
103. Barsky SH. Myoepithelial mRNA expression profiling reveals a com-
mon tumor-suppressor phenotype.
Exp Mol Pathol
2003;74:113–122.
104. Nguyen M, Lee MC, Wang JL, et al. The human myoepithelial
cell displays a multifaceted anti-angiogenic phenotype.
Oncogene
2000;19:3449–3459.
105. Shao ZM, Nguyen M. Alpaugh ML, et al. The human myoepithelial
cell exerts antiproliferative effects on breast carcinoma cells character-
ized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis.
Exp
Cell Res
1998;241:394–403.
106. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-
suppressing activity in human mammary epithelial cells.
Science
1994;263:526–529.
107. Adriance MC, Inman JL, Peterson OW, et al. Myoepithelial cells: good
fences make good neighbors.
Breast Cancer Res
2005;7:190–197.
108. AllinenM, BeroukhimR, Cai L, et al. Molecular characterization of the
tumor microenvironment in breast cancer.
Cancer Cell
2004;6:17–32.
109. SmithMC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both
primary and metastatic breast cancer.
Cancer Res
2004;64:8604–8612.
110. Muller A, Homey B, Soto H, et al. Involvement of chemokine recep-
tors in breast cancer metastasis.
Nature
2001;410:50–56.
111. Kawasaki T, Nakamura S, Sakamoto G, et al. Neuroendocrine duc-
tal carcinoma
in situ
(NE-DCIS) of the breast—comparative clinico-
pathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases.
Histopathology
2008;53:288–298.
112. Farshid G, Moinfar F, Meredith DJ, et al. Spindle cell ductal carci-
noma
in situ
. An unusual variant of ductal intra-epithelial neoplasia
that simulates ductal hyperplasia or a myoepithelial proliferation.
Vir-
chows Arch
2001;439:70–77.
113. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma
in situ
and the emer-
gence of diversity during breast cancer evolution.
Clin Cancer Res
2008;14:370–378.
114. Jansen SA. Ductal carcinoma
in situ
: detection, diagnosis, and char-
acterization with magnetic resonance imaging.
Semin Ultrasound CT
MR
2011;32:306–318.
115. Lennington WJ, Jensen RA, Dalton LW, et al. Ductal carcinoma
in situ
of the breast. Heterogeneity of individual lesions.
Cancer
1994;73:118–124.
116. Azzopardi JG, Ahmed A, Millis RR.
Problems in breast pathology
.
(
Major Problems in Pathology
, vol. 11). Philadelphia: W.B. Saunders,
1979:192–203.
117. Castellano I, Marchiò C, Tomatis M, et al. Micropapillary ductal car-
cinoma
in situ
of the breast: an inter-institutional study.
Mod Pathol
2010;23:260–269.
118. Aulmann S, Braun L, Mietzsch F, et al. Transitions between flat epi-
thelial atypia and low-grade ductal carcinoma
in situ
of the breast.
Am
J Surg Pathol
2012;36:1247–1252.
119. Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: in-
terobserver and intraobserver variability.
ModPathol
2011;24:917–923.
120. Wen P, Marsh WL. SMMHC-p63 cocktail improves detection of myo-
epithelial layer in high-grade ductal carcinoma
in-situ
.
Mod Pathol
2005;18(Suppl.):54a–55a.
121. Martin HM, Bateman AC, Theaker JM. Calcium oxalate (Weddellite)
crystals within ductal carcinoma
in situ
.
J Clin Pathol
1999;52:932.
68. Howard JH, Bland KI. Current management and treatment strategies
for breast cancer.
Curr Opin Obstet Gynecol
2012;24:44–48.
69. Lehman CD. Magnetic resonance imaging in the evaluation of ductal
carcinoma
in situ
.
J Natl Cancer Inst Monogr
2010;2010(41):150–151.
70. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter co-
hort study to refine management recommendations for women at
elevated familial risk of breast cancer: the EVA trial.
J Clin Oncol
2010;28:1450–1457.
71. Itakura K, Lessing J, Sakata T, et al. The impact of preoperative mag-
netic resonance imaging on surgical treatment and outcomes for duc-
tal carcinoma
in situ
.
Clin Breast Cancer
2011;11:33–38.
72. Ashikari R, Hajdu SI, Robbins GF. Intraductal carcinoma of the breast
(1960–1969).
Cancer
1971;28:1182–1187.
73. Westbrook KC, Gallager HS. Intraductal carcinoma of the breast. A
comparative study.
Am J Surg
1975;130:667–670.
74. Pandya S, Mackarem G, Lee AKC, et al. Ductal carcinoma
in situ
: the
impact of screening on clinical presentation and pathologic features.
Breast J
1998;4:146–151.
75. Rosen PP, Ashikari R, Thaler H, et al. A comparative study of some
pathologic features of mammary carcinoma in Tokyo, Japan and New
York, USA.
Cancer
1977;39:429–434.
76. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of
intraductal carcinoma of the breast.
Cancer
1989;63:731–741.
77. Rosen P, Snyder RE, Urban JA, et al. Correlation of suspicious mam-
mograms and X-rays of breast biopsies during surgery. Results in
60 cases.
Cancer
1973;31:656–660.
78. Snyder R, Rosen P. Radiography of breast specimens.
Cancer
1971;28:1608–1611.
79. Rosen PP. Frozen section diagnosis of breast lesions. Recent experi-
ence with 556 consecutive biopsies.
Ann Surg
1978;187:17–19.
80. Cheng L, Al-Kaisi NK, Liu AY, et al. The results of intraoperative
consultations in 181 ductal carcinomas
in situ
of the breast.
Cancer
1997;80:75–79.
81. Rosen PP, Senie R, Schottenfeld D, et al. Noninvasive breast carci-
noma: frequency of unsuspected invasion and implication for treat-
ment.
Ann Surg
1979;189:98–103.
82. Jorns JM, Visscher D, Sabel M, et al. Intraoperative frozen section
analysis of margins in breast conserving surgery significantly de-
creases reoperative rates: one-year experience at an ambulatory surgi-
cal center.
Am J Clin Pathol
2012;138:657–669.
83. Tramm T, Zuckerman K, Tavassoli FA. Skip lesion of DIN (DCIS)
in the nipple in a case of breast cancer.
Int J Surg Pathol
2011;19:
817–821.
84. Tunon-de-Lara C, André G, Macgrogan G, et al. Ductal carcinoma
in situ
of the breast: influence of age on diagnostic, therapeutic, and
prognostic features. Retrospective study of 812 patients.
Ann Surg On-
col
2011;18:1372–1379.
85. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, et al. Predictive fac-
tors for BRCA1/BRCA2 mutations in women with ductal carcinoma
in situ
.
Cancer
2012;118:1515–1522.
86. Bellamy COC, McDonald C, Salter DM, et al. Noninvasive ductal car-
cinoma of the breast: the relevance of histologic categorization.
Hum
Pathol
1993;24:16–23.
87. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma
of the breast (208 cases): clinical factors influencing treatment choice.
Cancer
1990;66:102–108.
88. Brown PW, Silverman J, Owens E, et al. Intraductal “noninfiltrating”
carcinoma of the breast.
Arch Surg
1976;111:1063–1067.
89. Urban JA. Biopsy of the “normal” breast in treating breast cancer.
Surg
Clin North Am
1969;49:291–301.
90. Ringberg A, Palmer B, Linell F. The contralateral breast at reconstruc-
tive surgery after breast cancer operation—a histological study.
Breast
Cancer Res Treat
1982;2:151–161.
91. GriffinA, Frazee RC. Treatment of intraductal breast cancer—noncomedo
type.
Am Surg
1993;59:106–109.
92. Schuh ME, Nemoto T, Penetrante RB, et al. Intraductal carcinoma.
Analysis of presentation, pathologic findings, and outcome of disease.
Arch Surg
1986;121:1303–1307.
93. Schwartz GF, Patchefsky AS, Finklestein SD, et al. Nonpalpable
in situ
ductal carcinoma of the breast. Predictors of multicentricity and mi-
croinvasion and implications for treatment.
Arch Surg
1989;124:29–32.
94. Habel LA, Moe RE, Daling JR, et al. Risk of contralateral breast can-
cer among women with carcinoma
in situ
of the breast.
Ann Surg
1997;225:69–75.
